研究-葡萄糖共运输体-2 (SGLT2) 抑制剂与血压之间的关系
Mohammed Kallash1, William Frishman
1From the School of Medicine, New York Medical College, Valhalla, NY.
Cardiology in review
|February 3, 2025
概括
-葡萄糖共运输体-2 (SGLT2) 抑制剂通过潜在的直接机制在大脑中降低血压. 需要进一步的研究来证实这种效应在人类中及其对高血压治疗的影响.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 起初用于2型糖尿病的-葡萄糖共运输体-2 (SGLT2) 抑制剂,在心力衰竭和慢性病中显示出心血管方面的益处.
- 它们的抗高血压作用是公认的,但还没有完全理解,像减肥和尿液流动这样的间接机制不足以解释它们的全部作用.
- 新出现的证据表明,直接机制涉及中枢神经系统.
研究的目的:
- 探索SGLT2抑制剂潜在的直接抗高血压机制.
- 研究SGLT2受体在大脑血压调节中的作用.
- 为了确定SGLT2抑制剂是否可以被视为主要抗高血压药物.
主要方法:
- 对SGLT2抑制剂对心血管和抗高血压作用的现有文献的综述.
- 对动物模型研究的分析确定了SGLT2受体在大脑中调节同情神经系统的区域.
- 检查动物模型中SGLT2抑制剂诱导的神经元活动和血压的抑制结果.
主要成果:
- 动物研究表明,SGLT2受体存在于控制交感神经系统和血压的大脑区域.
- 在动物模型中,SGLT2抑制剂在这些大脑区域抑制了神经元活动.
- 这种抑制导致交感神经系统活动减少,研究动物的血压降低.
结论:
- SGLT2 抑制剂可以通过调节中心交感外流来产生直接的抗高血压作用.
- 需要进一步的研究来确认SGLT2受体在人体中枢神经系统中的存在,以及药物对神经元活动的影响.
- 了解这种机制可以为初级高血压提供新的见解,并扩大SGLT2抑制剂在心血管和保护中的作用.
更多相关视频
10:35Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
Published on: April 6, 2022
2.7K
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
10.2K
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
162
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
162
01:16Antihypertensive Drugs: Action of Diuretics
613
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
613
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
146
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
146
01:17Oral Hypoglycemic Agents: Sulfonylureas
184
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
184
01:25Antihypertensive Drugs: Direct Renin Inhibitors
477
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
477
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
574
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
574